Zota Health Care Ltd Q2 FY26 | From Generic Dreams to Brand Nightmares – 92% YoY Sales Surge but ₹16 Cr Loss, DavaIndia Expands to 2,055 Stores!
1. At a Glance
If Dalal Street had a comedy club, Zota Health Care’s latest quarter would headline it. The ₹4,618 crore market-cap pharma minnow just delivered a jaw-dropping 92 % YoY revenue surge to ₹128.9 crore in Q2 FY26 — only to then trip over its own shoelaces and post a ₹16 crore loss. At ₹1,523 per share, the stock’s up 148 % in a year and 73 % in six months, making retail investors feel like pharmacists handing out free dopamine tablets. Book Value? ₹104. P/B? 14.6 times. ROE? -36 %. ROCE? -17 %. Clearly, the only thing compounding here is confusion.
A company that makes generics, ayurvedics, nutraceuticals and OTC products across 30 countries somehow can’t generate profit at home. DavaIndia — their low-cost generic retail arm — has hit 2,055 stores, but the balance sheet looks like it just swallowed its own capsule.
Will this “Generic Revolution” become the next Indian retail-pharma success story or another case study in over-expansion? Let’s pop open the blister pack.
2. Introduction
Once upon a time in Surat, a small-town chemist dreamt of becoming the next Sun Pharma. He didn’t have Deepak Mehta’s cash or Dilip Shanghvi’s calm, but he had ambition — and a DavaIndia logo that looked like a health app from the future.
Fast-forward to FY26: Zota Health Care is a ₹4,600 crore circus juggling pharma formulations, nutraceuticals, and franchisee retail with equal parts enthusiasm and chaos. They boast 3,000 + products, 1,050 + distributors, and dreams big enough to fit an entire chemist chain inside a single PowerPoint slide.
Yet, for all its “Make in India, Sell Everywhere” rhetoric, Zota’s P&L still bleeds like a bad injection. The R&D pipeline has 19 patents (7 granted) and the company’s mascot is literally Kapil Dev, because apparently nothing screams “pharmaceutical credibility” like a cricketer telling you to buy multivitamins.
So what’s going on behind those shiny QIP headlines, preferential issues, and the sudden 500-crore fundraising spree? We did what auditors won’t: we looked.
3. Business Model – WTF Do They Even Do?
Zota’s business model is basically a Bollywood plot — too many side characters, no clear hero.
Domestic Business (≈ 49 % of FY21 revenue) The OG division — distributing generic drugs and OTC products through 1,050 + distributors across India. Think of it as the “legacy Zota”: not sexy, but still paying the bills.
DavaIndia (≈ 22 %) The franchise pharmacy chain offering generics at 30 % – 90 % discounts. 2,055 stores across 24 states, mostly FOFO model — which basically means Zota prints invoices while franchisees cry quietly.
Exports (≈ 29 %) Spread over 30 countries in Africa, Asia, CIS and Latin America. 253 approved dossiers, 311 pending. A WHO-GMP plant in Surat’s SEZ keeps customs officials awake.
Digital & Nutraceuticals A mobile app (Nutravedic.com) to sell capsules with spiritual hashtags like #GlowFromWithin and #DetoxBeforeItWasCool.
So, basically — a little of everything, a lot of nothing yet profitable.
4. Financials Overview
Source table
Metric
Latest Qtr (Q2 FY26)
YoY (Q2 FY25)
Prev Qtr (Q1 FY26)
YoY %
QoQ %
Revenue (₹ Cr)
128.9
67.2
103.8
92.0 %
24.2 %
EBITDA (₹ Cr)
6
-6
4
+200 % (ish revival)
+50 %
PAT (₹ Cr)
-16.0
-11.9
-14.0
-34 %
-14 %
EPS (₹)
-5.26
-4.41
-4.81
Loss expands
Loss expands
Annualised EPS = -21.0 → P/E not meaningful.
Commentary: Revenue jumped like an energy-drink ad, but profits did the reverse long-jump. Operating margins at ~5 % barely cover interest costs. Clearly, DavaIndia’s “discount strategy” works for customers, not shareholders.
5. Valuation Discussion – Fair Value Range Only
We ran three classic methods to see where Zota might “technically” belong on paper. (Educational only, not financial advice.)
P/E Method (irrelevant for loss-making firm)
Let’s pretend profit existed with a future EPS of ₹10 (after turnaround) and assign industry P/E of 30 → ₹300 fair value. Reality check: EPS is -21.
EV/EBITDA Method
EV = ₹ 4,794 cr, EBITDA ≈ ₹ 7 cr → EV/EBITDA = 685 ×. That’s not valuation — that’s hallucination. Even Divi’s Lab doesn’t get that multiple on its birthday.
If normalized EBITDA rises to ₹ 100 cr over 3 years (from scale and retail maturity), EV/EBITDA range of 25–35 would imply fair value ₹ 2,500–3,500 cr (₹ 820–1,150 per share).
